Paris - Delayed Quote EUR

Cellectis S.A. (ALCLS.PA)

Compare
1.8360 +0.0080 (+0.44%)
At close: October 18 at 5:35 PM GMT+2

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Dr. Andre Choulika Ph.D. Co-Founder, CEO & Director 784.28k -- 1965
Dr. David j. d. Sourdive Ph.D. Deputy CEO, Executive VP of CMC & Manufacturing and Director 499.09k -- 1967
Mr. Arthur Stril Interim Chief Financial Officer -- -- 1989
Valerie Cros Principal Financial Officer & Principal Accounting Officer -- -- --
Mr. Jean Charles Epinat Chief Technological Officer -- -- --
Dr. Philippe Duchateau Ph.D. Chief Scientific Officer -- -- 1963
Ms. Marie-Bleuenn Terrier General Counsel & Secretary of the Board of Directors -- -- 1982
Pascalyne Wilson Director of Communications -- -- --
Ms. Kyung Nam-Wortman Executive VP & Chief Human Resources Officer -- -- 1970
Mr. Stephan Reynier M.Sc. Chief Regulatory & Pharmaceutical Compliance Officer -- -- 1969

Cellectis S.A.

8, rue de la Croix Jarry
Paris, 75013
France
33 1 81 69 16 00 https://www.cellectis.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
216

Description

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Corporate Governance

Cellectis S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 4, 2024 at 3:00 PM UTC - November 8, 2024 at 3:00 PM UTC

Cellectis S.A. Earnings Date

Recent Events

Related Tickers